P. Soden

发表

Aβ1–42 reduces synapse number and inhibits neurite outgrowth in primary cortical and hippocampal neurons: A quantitative analysis

R. Prinjha, J. Richardson, N. Evans, 2008, Journal of Neuroscience Methods.

Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit.

P. Soden, N. Lamadema, Christopher J. Matthews, 2013, Journal of medicinal chemistry.

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

S. Robson, G. Drewes, M. Bantscheff, 2011, Nature.

The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor.

Christophe Simon, P. Bamborough, R. Prinjha, 2014, Journal of medicinal chemistry.

Application of Atypical Acetyl-Lysine Methyl Mimetics in the Development of Selective Inhibitors of the Bromodomain-Containing Protein 7 (BRD7)/Bromodomain-Containing Protein 9 (BRD9) Bromodomains.

Melanie V. Leveridge, P. Grandi, A. Michon, 2020, Journal of medicinal chemistry.

Dishevelled Regulates the Metabolism of Amyloid Precursor Protein via Protein Kinase C/Mitogen-Activated Protein Kinase and c-Jun Terminal Kinase

S. Lovestone, P. Soden, T. Golde, 2001, The Journal of Neuroscience.

Summary. A transgenic mouse bearing mutant transgenes linked to familial forms of Alzheimer’s disease (AD) for the amyloid precursor protein and presenilin-1 (TASTPM) showed Aß plaque deposition and age-related histological changes in associated brain

J. Richardson, P. Soden, S. Burbidge, 2007 .

Oxidative neuropathology and putative chemical entities for alzheimer’s disease: Neuroprotective effects of salen-manganese catalytic anti-oxidants

J. Barnes, P. Soden, S. Doctrow, 2009, Neurotoxicity Research.

Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation

P. Grandi, A. Michon, G. Drewes, 2020, Science.

GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins.

P. Grandi, P. Bamborough, R. Prinjha, 2020, Journal of medicinal chemistry.

Abeta deposition and related pathology in an APP x PS1 transgenic mouse model of Alzheimer's disease.

J. Richardson, P. Soden, S. Burbidge, 2008, Histology and histopathology.

A randomized study of the safety and pharmacokinetics of GSK3358699, a mononuclear myeloid‐targeted bromodomain and extra‐terminal domain inhibitor

R. Prinjha, P. Soden, W. Fahy, 2021, British journal of clinical pharmacology.

MAPK-activated Protein Kinase 2 Deficiency in Microglia Inhibits Pro-inflammatory Mediator Release and Resultant Neurotoxicity

J. Richardson, M. Gaestel, N. Evans, 2006, Journal of Biological Chemistry.

The structure based design of dual HDAC/BET inhibitors as novel epigenetic probes

Kathryn A. Giblin, G. Drewes, M. Bantscheff, 2014 .

Ultrastructural and behavioural changes precede amyloid deposition in a transgenic model of Alzheimer’s disease

J. Barnes, M. Stewart, J. Richardson, 2003, Neuroscience.

Oxidative signalling and inflammatory pathways in Alzheimer's disease.

J. Barnes, P. Soden, S. Doctrow, 2001, Biochemical Society symposium.

Oligodendrocytes are a Novel Source of Amyloid Peptide Generation

J. Richardson, N. Evans, L. Facci, 2009, Neurochemical Research.

Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression.

R. Prinjha, P. Soden, C. Chung, 2021, Journal of medicinal chemistry.

Elevated levels of amyloid precursor protein in muscle of patients with amyotrophic lateral sclerosis and a mouse model of the disease

R. Prinjha, P. Soden, H. Koistinen, 2006, Muscle & nerve.

Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.

James M. Woolven, P. Bamborough, R. Prinjha, 2020, Journal of medicinal chemistry.

Design and Characterization of 1,3-Dihydro-2H-benzo[d]azepin-2-ones as Rule-of-5 Compliant Bivalent BET Inhibitors.

P. Bamborough, R. Prinjha, P. Soden, 2023, ACS medicinal chemistry letters.

Aβ1–42 reduces synapse number and inhibits neurite outgrowth in primary cortical and hippocampal neurons: A quantitative analysis

R. Prinjha, N. Evans, L. Facci, 2008, Journal of Neuroscience Methods.